297 related articles for article (PubMed ID: 22538522)
41. A 67-year-old woman receiving tumor necrosis factor α inhibitor therapy presenting with neurologic dysfunction.
Garg N; Woltjer R; Hamilton B; Neuwelt EA; Rosenbaum JT
Arthritis Care Res (Hoboken); 2013 Apr; 65(4):658-65. PubMed ID: 23203566
[No Abstract] [Full Text] [Related]
42. Relative efficacies: antimalarials to abatacept - the choice is ours.
Russell AS
J Rheumatol Suppl; 2009 Jun; 82():17-24. PubMed ID: 19509326
[TBL] [Abstract][Full Text] [Related]
43. Optic neuritis after infliximab therapy.
Faillace C; de Almeida JR; de Carvalho JF
Rheumatol Int; 2013 Apr; 33(4):1101-3. PubMed ID: 22198693
[TBL] [Abstract][Full Text] [Related]
44. [Mechanism of action of biological disease--modifying antirheumatic drugs].
Takahashi N; Ishiguro N
Nihon Rinsho; 2016 Jun; 74(6):882-6. PubMed ID: 27311173
[No Abstract] [Full Text] [Related]
45. Systemic nocardiosis in a case of rheumatoid arthritis treated with tumor necrosis factor blockers.
Wendling D; Murad M; Mathieu S; Berger E; Rumbach L
J Rheumatol; 2008 Mar; 35(3):539-42. PubMed ID: 18322977
[No Abstract] [Full Text] [Related]
46. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.
Hernández MV; Sanmartí R; Cañete JD
Expert Opin Drug Saf; 2016 May; 15(5):613-24. PubMed ID: 26927029
[TBL] [Abstract][Full Text] [Related]
47. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.
Rajakulendran S; Gadsby K; Allen D; O'Reilly S; Deighton C
Ann Rheum Dis; 2006 Dec; 65(12):1678-9. PubMed ID: 17105865
[No Abstract] [Full Text] [Related]
48. Polymyositis associated with infliximab treatment for rheumatoid arthritis.
Urata Y; Wakai Y; Kowatari K; Nitobe T; Mizushima Y
Mod Rheumatol; 2006; 16(6):410-1. PubMed ID: 17165006
[No Abstract] [Full Text] [Related]
49. Tumour necrosis factor blockade in rheumatoid arthritis.
Breedveld FC
Clin Med (Lond); 2001; 1(2):107-9. PubMed ID: 11333452
[No Abstract] [Full Text] [Related]
50. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.
Vandevyvere K; Luyten FP; Verschueren P; Lories R; Segaert S; Westhovens R
Clin Rheumatol; 2007 Dec; 26(12):2205-2206. PubMed ID: 17876646
[No Abstract] [Full Text] [Related]
51. Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis.
Wakefield RJ; Freeston JE; Hensor EM; Bryer D; Quinn MA; Emery P
Arthritis Rheum; 2007 Dec; 57(8):1564-7. PubMed ID: 18050231
[No Abstract] [Full Text] [Related]
52. When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?
Smolen JS; Weinblatt ME
Ann Rheum Dis; 2008 Nov; 67(11):1497-8. PubMed ID: 18854512
[No Abstract] [Full Text] [Related]
53. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Dougados M; Emery P; Gibofsky A; Kavanaugh AF; Keystone EC; Klareskog L; Russell AS; van de Putte LB; Weisman MH
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii2-9. PubMed ID: 14532138
[No Abstract] [Full Text] [Related]
54. Development of alopecia areata universalis in a patient receiving adalimumab.
Garcia Bartels N; Lee HH; Worm M; Burmester GR; Sterry W; Blume-Peytavi U
Arch Dermatol; 2006 Dec; 142(12):1654-5. PubMed ID: 17179003
[No Abstract] [Full Text] [Related]
55. [Cutaneous rash from the use of medicine for rheumatoid arthritis].
Hannuksela M
Duodecim; 2006; 122(1):105, 111. PubMed ID: 16509198
[No Abstract] [Full Text] [Related]
56. Rheumatoid arthritis and tuberculosis in the tumor necrosis factor inhibitors era: observations from Brazil.
da Rocha Castelar Pinheiro G
J Clin Rheumatol; 2005 Dec; 11(6):344-6. PubMed ID: 16371812
[No Abstract] [Full Text] [Related]
57. Comments on Falgarone et al. editorial entitled "TNFalpha antagonists in rheumatoid arthritis patients seen in everyday practice".
Legoff P
Joint Bone Spine; 2008 Oct; 75(5):626; author reply 626. PubMed ID: 18805723
[No Abstract] [Full Text] [Related]
58. Treatment of rheumatoid arthritis: we are getting there.
Yazici Y
Lancet; 2009 Jul; 374(9685):178-80. PubMed ID: 19560809
[No Abstract] [Full Text] [Related]
59. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis.
Fleischmann RM; Iqbal I; Stern RL
Expert Opin Drug Saf; 2004 Sep; 3(5):391-403. PubMed ID: 15335295
[TBL] [Abstract][Full Text] [Related]
60. Recombinant DNA product for rheumatoid arthritis.
FDA Consum; 2003; 37(2):5. PubMed ID: 12715755
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
